tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Sciatic Neuropathy D020426 13 associated lipids
Corneal Diseases D003316 13 associated lipids
Glucose Intolerance D018149 13 associated lipids
Bradycardia D001919 13 associated lipids
Sarcoidosis D012507 13 associated lipids
Multiple Myeloma D009101 13 associated lipids
Rosacea D012393 13 associated lipids
Hematuria D006417 13 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Uveitis D014605 14 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Alopecia D000505 14 associated lipids
Stomatitis D013280 14 associated lipids
Vasculitis D014657 14 associated lipids
Hemorrhage D006470 15 associated lipids
Neutropenia D009503 15 associated lipids
HIV Seropositivity D006679 15 associated lipids
Tremor D014202 15 associated lipids
Encephalitis D004660 15 associated lipids
Dyskinesia, Drug-Induced D004409 15 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Burkitt Lymphoma D002051 15 associated lipids
Thymus Neoplasms D013953 15 associated lipids
Testicular Diseases D013733 15 associated lipids
Thrombocytopenia D013921 15 associated lipids
Choline Deficiency D002796 16 associated lipids
Cholelithiasis D002769 16 associated lipids
Peritoneal Neoplasms D010534 16 associated lipids
Vascular Diseases D014652 16 associated lipids
Ulcer D014456 16 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Gram-Negative Bacterial Infections D016905 16 associated lipids
Brain Infarction D020520 17 associated lipids
Leukemia, Myelogenous, Chronic, BCR-ABL Positive D015464 17 associated lipids
Subarachnoid Hemorrhage D013345 17 associated lipids
Liver Cirrhosis, Alcoholic D008104 17 associated lipids
Dermatomycoses D003881 17 associated lipids
Mycoses D009181 18 associated lipids
Lymphoma D008223 18 associated lipids
Ischemia D007511 18 associated lipids
Albuminuria D000419 18 associated lipids
Down Syndrome D004314 18 associated lipids
Peptic Ulcer D010437 19 associated lipids
Pregnancy Complications D011248 19 associated lipids
Cough D003371 19 associated lipids
Nephritis D009393 19 associated lipids
Hypothermia D007035 19 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Parkinsonian Disorders D020734 20 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gaweco AS et al. Distinct intragraft cytokine gene expression patterns during acute hepatic rejection under cyclosporine versus FK 506 primary immunosuppression. 1994 Transplant. Proc. pmid:7527948
Burke GW et al. The use of FK506 in simultaneous pancreas/kidney transplantation: rescue, induction, and maintenance immunosuppression. 1995 Transplant. Proc. pmid:8539874
Valdivia LA et al. Hamster-to-rat liver xenografts protect extrahepatic organs from rejection. 1993 Transplant. Proc. pmid:7679816
Yasunami Y et al. Acceptance of donor-specific islet allografts in rat by intraportal preimmunization with islets and FK 506. 1994 Transplant. Proc. pmid:7513467
Meier-Kriesche HU and Kaplan B Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared to Sandimmune. 2001 Nov-Dec Transplant. Proc. pmid:11750465
Alejandro R et al. Combined liver-islet allotransplantation in man under FK 506. 1991 Transplant. Proc. pmid:1703712
Uchida K et al. Decreasing pancreatic toxicity of tacrolimus by dosage reduction. 1998 Transplant. Proc. pmid:9636518
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk". 2000 Transplant. Proc. pmid:11119893
Gołębiewska J et al. Tako-tsubo cardiomyopathy on the first day after renal transplantation - case report and literature review. 2014 Transplant. Proc. pmid:25380951
Kanter J et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. 2009 Jul-Aug Transplant. Proc. pmid:19715860
Bilbao I et al. Indications and management of everolimus after liver transplantation. 2009 Jul-Aug Transplant. Proc. pmid:19715864
TuÄŸcu M et al. Tacrolimus-Induced Diabetic Ketoacidosis and Effect of Switching to Everolimus: A Case Report. 2015 Transplant. Proc. pmid:26093759
García-Meseguer C et al. Efficacy and safety of basiliximab in pediatric renal transplantation. 2002 Transplant. Proc. pmid:11959206
Rafael-Valdivia L et al. How long should initiation of calcineurin inhibitors be delayed to protect renal function in liver transplantation? 2011 Transplant. Proc. pmid:21486577
Charco R et al. A prospective, multicenter study of once-daily extended-release tacrolimus in de novo liver transplant recipients. 2011 Transplant. Proc. pmid:21486582
Alessiani M et al. Infections with FK 506 immunosuppression: preliminary results with primary therapy. 1990 Transplant. Proc. pmid:1689895
Fung J et al. Randomized trial in primary liver transplantation under immunosuppression with FK 506 or cyclosporine. 1993 Transplant. Proc. pmid:7680146
Shibata T et al. Does FK 506 accelerate the development of coronary artery disease in the transplanted heart as well as the native heart? 1993 Transplant. Proc. pmid:7680147
Wu YM et al. Interaction between FK 506 and cyclosporine in dogs. 1991 Transplant. Proc. pmid:1721281
Andereggen E et al. Immunohistological study of islet xenograft rejection in immunosuppressed recipients. 1996 Transplant. Proc. pmid:8623420
Horimoto H et al. Hepatocyte xenotransplantation for Nagase's analbuminemic rats: the effect of FK506. 1996 Transplant. Proc. pmid:8623421
Klupp J et al. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation. 1998 Transplant. Proc. pmid:9636585
Fujikawa K et al. Effects of tacrolimus on rat thymic epithelial cells. 2000 Transplant. Proc. pmid:11120046
Jordan ML et al. Tacrolimus-based immunosuppression in pediatric renal transplantation. 1999 Transplant. Proc. pmid:10576039
Martín-Mateos RM et al. Initial immunosuppression with or without basiliximab: a comparative study. 2012 Transplant. Proc. pmid:23146457
Nakamuta M et al. Cyclosporine suppresses cell growth and collagen production in hepatic stellate cells. 2005 Transplant. Proc. pmid:16387179
Kim HC et al. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. 2004 Transplant. Proc. pmid:15518753
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Yasutomi M et al. Mechanism of antibody production in hamster-to-rat concordant xenotransplantation: establishment of a simple model using intravenous injection of concordant splenocytes. 1994 Transplant. Proc. pmid:7518110
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Mueller AR et al. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A. 1995 Transplant. Proc. pmid:7533359
Wang SC et al. FK 506, rapamycin, and cyclosporine: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. 1991 Transplant. Proc. pmid:1721312
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Villamil F et al. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. 2006 Transplant. Proc. pmid:17112875
Woo J et al. Kinetics of early T-cell repopulation in the mouse following syngeneic bone marrow transplantation: FK 506 causes a maturational defect of CD4+ CD8- T cells. 1991 Transplant. Proc. pmid:1721313
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
Lischke R et al. Initial single-center experience with sirolimus after lung transplantation. 2006 Transplant. Proc. pmid:17112886
Moreno Gonzales M et al. Sublingual Tacrolimus in Liver Transplantation: A Valid Option? Transplant. Proc. pmid:27569953
Wang CH et al. The impact on biochemical profiles and allograft function for patients converted from cyclosporine to tacrolimus after clinical heart transplantation. 2008 Transplant. Proc. pmid:18929812
Wang SS et al. Heart transplantation under cyclosporine or tacrolimus combined with mycophenolate mofetil or everolimus. 2008 Transplant. Proc. pmid:18929814
Ennaifer R et al. Nodular hyperplasia of the gastrointestinal tract after liver transplantation: role of immunosuppressive therapy? A case report. 2015 Transplant. Proc. pmid:25891739
Yang YJ et al. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency. 2008 Transplant. Proc. pmid:18589147
Jain A et al. Steroid withdrawal under tacrolimus for primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune hepatitis after liver transplantation and long-term survival. 2002 Transplant. Proc. pmid:12176467
Masri MA Comparative study of toxicity and efficacy of cyclosporine, cyclosporine G (OG37), FK 506, and rapamycin in BALB/c mice with fitted skin grafts. 1995 Transplant. Proc. pmid:7533412
Brunet M et al. Therapeutic drug monitoring of tacrolimus in kidney transplantation: 9-month follow-up. 1998 Transplant. Proc. pmid:9865298
Nakazato P et al. Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506. 1991 Transplant. Proc. pmid:1721345
Wasiak D et al. Delayed, Uncommon Recurrence of Hepatocellular Carcinoma After Liver Transplantation: A Case Report. 2016 Transplant. Proc. pmid:27496507
Numakura K et al. Incidence and risk factors of clinical characteristics, tacrolimus pharmacokinetics, and related genomic polymorphisms for posttransplant diabetes mellitus in the early stage of renal transplant recipients. 2005 Transplant. Proc. pmid:15919487
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Velio P et al. Combined orthotopic liver-small bowel transplantation or small bowel transplantation in pigs: relations between survival, rejection, and mucosal morphometry. 1997 Transplant. Proc. pmid:9142295
Varo E et al. Incidence of cytomegalovirus infection and disease in orthotopic liver transplant patients immunosuppressed with cyclosporin versus tacrolimus. 2002 Transplant. Proc. pmid:12176488
De Ruvo N et al. Preliminary results of immunosuppression with thymoglobuline pretreatment and hepatitis C virus recurrence in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182760
Imanishi M et al. Induction of tolerance by intrathymic injection of donor bone marrow cells in the rat: simultaneous heart and skin allograft model. 1994 Transplant. Proc. pmid:7520615
Matsuura T et al. Organ-specific tolerance induced by intrathymic injection of donor bone marrow cells and FK 506 or antilymphocyte serum in rat heart transplantation. 1994 Transplant. Proc. pmid:7520616
Jeong HJ et al. Vascular endothelin, TGF-beta, and PDGF expression in FK506 nephrotoxicity of rats. 1998 Transplant. Proc. pmid:9838576
Lieberman KV et al. FK 506 is a direct glomeruloconstrictor, as determined by electrical resistance pulse sizing (ERPS). 1991 Transplant. Proc. pmid:1721376
Yura H et al. Development of a macromolecular prodrug of FK506: I. Synthesis of FK506-dextran conjugate. 1998 Transplant. Proc. pmid:9838577
Demetris AJ et al. Histopathology of human renal allograft rejection under FK 506: a comparison with cyclosporine. 1991 Transplant. Proc. pmid:1703360
Ueda D et al. Influence of FK 506 on renal blood flow. 1991 Transplant. Proc. pmid:1721377
Lohmann R et al. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083151
Thomson AW et al. The influence of FK 506 on the thymus: implications of drug-induced injury to thymic epithelial cells. 1991 Transplant. Proc. pmid:1703361
Kato T et al. Mycophenolate mofetil rescue therapy in patients with chronic hepatic allograft rejection. 1999 Feb-Mar Transplant. Proc. pmid:10083158
Song Z et al. Protective effect of FK-506 in pig-to-rat islet xenotransplantation is abrogated by prednisolone. 2000 Transplant. Proc. pmid:10936332
Morozumi K et al. Electron-microscopic peritubular capillary lesion is a specific and useful diagnostic indicator for chronic rejection of renal allografts showing less specific morphologic lesions in the cyclosporine era. 1997 Feb-Mar Transplant. Proc. pmid:9123167
Nishioka T et al. Arterial stiffness after successful renal transplantation. 2008 Transplant. Proc. pmid:18790249
Sola E et al. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil. 2002 Transplant. Proc. pmid:12176537
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Utsugi R et al. Tolerance across a two-haplotype, fully MHC-mismatched barrier induced in miniature swine renal allografts treated with a 12-day course of tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11266727
Madariaga JR et al. The long-term efficacy of multivisceral transplantation. 2000 Transplant. Proc. pmid:10995918
Pelekanou V et al. FK 506 and rapamycin do not affect platelet aggregation or mitochondrial function. 1991 Transplant. Proc. pmid:1721408
Taki J et al. DNA analysis of peripheral blood mononuclear cells for early detection of hepatic graft rejection. 1992 Transplant. Proc. pmid:1379760
Schorlemmer HU et al. Coadministration of malononitrilamides and tacrolimus induces tolerance in a rat skin allograft model. 1999 Feb-Mar Transplant. Proc. pmid:10083529
Fishbein T et al. Isolated intestinal transplantation in adults with nonreconstructible GI tracts. 2000 Transplant. Proc. pmid:10995925
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Ju MK et al. Is the affinity column-mediated immunoassay method suitable as an alternative to the microparticle enzyme immunoassay method as a blood tacrolimus assay? 2008 Transplant. Proc. pmid:19100463
McCarter JF et al. FK 506 protects brain tissue in animal models of stroke. 2001 Transplant. Proc. pmid:11377571
Wen J et al. Tripterygium wilfordii hook f increase the blood concentration of tacrolimus. 2008 Transplant. Proc. pmid:19100464
Baran DA et al. Predictors of early renal insufficiency in cardiac transplant recipients initiated on tacrolimus. 2002 Transplant. Proc. pmid:12176609
van Gelder T et al. ATP-binding cassette transporters and calcineurin inhibitors: potential clinical implications. 2001 Transplant. Proc. pmid:11377580
Fieguth HG et al. Tacrolimus for treatment of bronchiolitis obliterans syndrome after unilateral and bilateral lung transplantation. 2002 Transplant. Proc. pmid:12176613
Lorenzini S et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: a report of four cases. 2006 Transplant. Proc. pmid:16797338
Quiroga I et al. Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. 2001 Feb-Mar Transplant. Proc. pmid:11267261
Sato K et al. Comparative study of FK 506, cyclosporine, and triple regimen immunosuppression with FK 506, cyclosporine, and mizoribine. 1991 Transplant. Proc. pmid:1721440
Odocha O et al. Posttransplant diabetes mellitus in African Americans after renal transplantation under FK 506 immunosuppression. 1993 Transplant. Proc. pmid:7689268
Ochiai T et al. Effects of FK-506 on xenotransplantation of the heart and skin in a mouse-rat combination. 1987 Transplant. Proc. pmid:2445083
Dumortier J et al. Introduction of mycophenolate mofetil in maintenance liver transplant recipients: what can we expect? Results of a 10-year experience. 2010 Transplant. Proc. pmid:20832553
Yonan NA et al. Tracheal allograft transplantation in rats: the role of immunosuppressive agents in development of obliterative airway disease. 1998 Transplant. Proc. pmid:9723443
Greenstein SM et al. Nifedipine prevents tacrolimus-induced intestinal hemodynamic and functional impairments. 1998 Transplant. Proc. pmid:9745540
Valenzuela M et al. Early steroid withdrawal in pediatric renal transplantation at a single center: preliminary report. 2008 Transplant. Proc. pmid:19010242
Aidong W et al. Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation. 2004 Transplant. Proc. pmid:15561258
Fung JJ et al. Current status of FK 506 in liver transplantation. 1991 Transplant. Proc. pmid:1712133
McCauley J et al. Long-term lipid metabolism in combined kidney-pancreas transplant recipients under tacrolimus immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267475
Lo A et al. Limited benefits of induction with monoclonal antibody to interleukin-2 receptor in combination with tacrolimus, mycophenolate mofetil, and steroids in simultaneous kidney-pancreas transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267477
Granot E et al. Monitoring of Epstein-Barr virus serology in children after liver transplant: lack of clinical correlation. 2000 Transplant. Proc. pmid:10856551
Undre NA et al. Pharmacokinetics of tacrolimus (FK506) in primary orthotopic heart transplant patients. 1998 Transplant. Proc. pmid:9636451
Walker RE et al. Clinical outcomes associated with conversion to tacrolimus-based immunosuppression in pediatric cardiac transplantation. 1998 Transplant. Proc. pmid:9636452
Soh KS et al. Simultaneous liver and kidney transplantation from different living donors. 2012 Transplant. Proc. pmid:22410057